Logo image of CTIC

CTI BIOPHARMA CORP (CTIC) Stock Fundamental Analysis

USA - NASDAQ:CTIC - US12648L6011 - Common Stock

9.09 USD
0 (0%)
Last: 6/23/2023, 8:00:00 PM
9.09 USD
0 (0%)
After Hours: 6/23/2023, 8:00:00 PM
Fundamental Rating

3

CTIC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. CTIC may be in some trouble as it scores bad on both profitability and health. CTIC is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTIC had negative earnings in the past year.
CTIC had a negative operating cash flow in the past year.
In the past 5 years CTIC always reported negative net income.
In the past 5 years CTIC always reported negative operating cash flow.
CTIC Yearly Net Income VS EBIT VS OCF VS FCFCTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for CTIC are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTIC Yearly ROA, ROE, ROICCTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

The Gross Margin of CTIC (94.11%) is better than 95.66% of its industry peers.
In the last couple of years the Gross Margin of CTIC has remained more or less at the same level.
CTIC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.05%
CTIC Yearly Profit, Operating, Gross MarginsCTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

CTIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTIC has been increased compared to 1 year ago.
Compared to 1 year ago, CTIC has a worse debt to assets ratio.
CTIC Yearly Shares OutstandingCTIC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CTIC Yearly Total Debt VS Total AssetsCTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M

2.2 Solvency

Based on the Altman-Z score of -27.07, we must say that CTIC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CTIC (-27.07) is worse than 88.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.07
ROIC/WACCN/A
WACC8.93%
CTIC Yearly LT Debt VS Equity VS FCFCTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

CTIC has a Current Ratio of 1.27. This is a normal value and indicates that CTIC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CTIC (1.27) is worse than 84.24% of its industry peers.
A Quick Ratio of 1.26 indicates that CTIC should not have too much problems paying its short term obligations.
CTIC's Quick ratio of 1.26 is on the low side compared to the rest of the industry. CTIC is outperformed by 83.28% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.26
CTIC Yearly Current Assets VS Current LiabilitesCTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

CTIC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.46%, which is quite impressive.
Looking at the last year, CTIC shows a very strong growth in Revenue. The Revenue has grown by 3201.48%.
The Revenue has been growing by 16.49% on average over the past years. This is quite good.
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
Revenue 1Y (TTM)3201.48%
Revenue growth 3Y152.53%
Revenue growth 5Y16.49%
Sales Q2Q%950.81%

3.2 Future

CTIC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.18% yearly.
CTIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.28% yearly.
EPS Next Y66.63%
EPS Next 2Y57.35%
EPS Next 3Y40.69%
EPS Next 5Y31.18%
Revenue Next Year121.03%
Revenue Next 2Y111.79%
Revenue Next 3Y81.8%
Revenue Next 5Y57.28%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTIC Yearly Revenue VS EstimatesCTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CTIC Yearly EPS VS EstimatesCTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTIC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 22.47, the valuation of CTIC can be described as rather expensive.
CTIC's Price/Forward Earnings ratio is rather cheap when compared to the industry. CTIC is cheaper than 95.34% of the companies in the same industry.
CTIC is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.92, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 22.47
CTIC Price Earnings VS Forward Price EarningsCTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTIC Per share dataCTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTIC's earnings are expected to grow with 40.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.35%
EPS Next 3Y40.69%

More info and screens

0

5. Dividend

5.1 Amount

CTIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CTI BIOPHARMA CORP

NASDAQ:CTIC (6/23/2023, 8:00:00 PM)

After market: 9.09 0 (0%)

9.09

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2023-05-15/amc
Earnings (Next)08-07 2023-08-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners16.2%
Ins Owner Change0%
Market Cap1.20B
Revenue(TTM)75.77M
Net Income(TTM)-69239000
Analysts75.71
Price Target10.7 (17.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend2.39
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.21%
Min EPS beat(2)-41.98%
Max EPS beat(2)15.56%
EPS beat(4)2
Avg EPS beat(4)-2.49%
Min EPS beat(4)-41.98%
Max EPS beat(4)18.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.51%
Min Revenue beat(2)-12.04%
Max Revenue beat(2)3.03%
Revenue beat(4)3
Avg Revenue beat(4)7.01%
Min Revenue beat(4)-12.04%
Max Revenue beat(4)32.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.9%
PT rev (3m)-6.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-3674.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.47
P/S 15.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.4
Fwd EY4.45%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.57
BVpS-0.19
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.11%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.05%
F-Score3
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.26
Altman-Z -27.07
F-Score3
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
EPS Next Y66.63%
EPS Next 2Y57.35%
EPS Next 3Y40.69%
EPS Next 5Y31.18%
Revenue 1Y (TTM)3201.48%
Revenue growth 3Y152.53%
Revenue growth 5Y16.49%
Sales Q2Q%950.81%
Revenue Next Year121.03%
Revenue Next 2Y111.79%
Revenue Next 3Y81.8%
Revenue Next 5Y57.28%
EBIT growth 1Y52.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.55%
OCF growth 3YN/A
OCF growth 5YN/A

CTI BIOPHARMA CORP / CTIC FAQ

What is the fundamental rating for CTIC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTIC.


Can you provide the valuation status for CTI BIOPHARMA CORP?

ChartMill assigns a valuation rating of 3 / 10 to CTI BIOPHARMA CORP (CTIC). This can be considered as Overvalued.


What is the profitability of CTIC stock?

CTI BIOPHARMA CORP (CTIC) has a profitability rating of 1 / 10.


How financially healthy is CTI BIOPHARMA CORP?

The financial health rating of CTI BIOPHARMA CORP (CTIC) is 1 / 10.


Can you provide the expected EPS growth for CTIC stock?

The Earnings per Share (EPS) of CTI BIOPHARMA CORP (CTIC) is expected to grow by 66.63% in the next year.